Tudor Investment Corp ET AL reduced its stake in Endo International PLC (NASDAQ:ENDP) (TSE:ENL) by 52.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 54,796 shares of the company’s stock after selling 59,620 shares during the period. Tudor Investment Corp ET AL’s holdings in Endo International PLC were worth $612,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. James Investment Research Inc. bought a new stake in shares of Endo International PLC in the 2nd quarter worth about $113,000. Blair William & Co. IL bought a new stake in shares of Endo International PLC in the 2nd quarter worth about $126,000. Point View Wealth Management Inc. increased its holdings in shares of Endo International PLC by 16.6% in the 2nd quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock worth $149,000 after buying an additional 1,900 shares during the last quarter. Riverhead Capital Management LLC increased its holdings in shares of Endo International PLC by 64.4% in the 2nd quarter. Riverhead Capital Management LLC now owns 15,025 shares of the company’s stock worth $168,000 after buying an additional 5,887 shares during the last quarter. Finally, Bank of Hawaii bought a new stake in shares of Endo International PLC in the 2nd quarter worth about $180,000. Institutional investors own 90.71% of the company’s stock.
Shares of Endo International PLC (NASDAQ ENDP) opened at 7.64 on Wednesday. Endo International PLC has a 12 month low of $7.40 and a 12 month high of $21.87. The firm has a 50-day moving average price of $8.67 and a 200 day moving average price of $10.54. The firm’s market capitalization is $1.71 billion.
Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.74 by $0.19. The business had revenue of $875.73 million for the quarter, compared to analyst estimates of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. Endo International PLC’s quarterly revenue was down 4.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.86 EPS. On average, analysts anticipate that Endo International PLC will post $3.52 EPS for the current fiscal year.
In related news, CFO Blaise Coleman purchased 6,500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 15th. The shares were acquired at an average price of $7.89 per share, with a total value of $51,285.00. Following the purchase, the chief financial officer now directly owns 13,729 shares in the company, valued at $108,321.81. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Terrance J. Coughlin purchased 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 10th. The stock was bought at an average cost of $7.70 per share, for a total transaction of $154,000.00. Following the purchase, the chief operating officer now owns 181,369 shares in the company, valued at $1,396,541.30. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 36,000 shares of company stock worth $279,460. 0.50% of the stock is owned by insiders.
ENDP has been the subject of a number of recent analyst reports. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. ValuEngine cut shares of Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Deutsche Bank AG lowered their price objective on shares of Endo International PLC from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Friday, July 7th. Zacks Investment Research cut shares of Endo International PLC from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Finally, BidaskClub raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, July 19th. Three analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and five have issued a buy rating to the stock. Endo International PLC presently has a consensus rating of “Hold” and a consensus target price of $12.64.
Endo International PLC Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with our FREE daily email newsletter.